ERIS Lifesciences' Q3 FY 2025-26 Quarterly Results
- 14 Feb 2026
Result Summary
- ERIS Lifesciences Ltd reported a 1.5% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 10.4%.
- Its expenses for the quarter were up by 3.6% QoQ and 4.8% YoY.
- The net profit decreased 19.1% QoQ and increased 25.2% YoY.
- The earnings per share (EPS) of ERIS Lifesciences Ltd stood at 7.31 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 807.47 | 795.22 | 731.67 | 1.5% | 10.4% |
Total Expenses | 645.00 | 622.83 | 615.51 | 3.6% | 4.8% |
Profit Before Tax | 145.23 | 172.39 | 116.16 | -15.8% | 25.0% |
Tax | 36.52 | 38.20 | 29.23 | -4.4% | 24.9% |
Profit After Tax | 108.83 | 134.47 | 86.93 | -19.1% | 25.2% |
Earnings Per Share | 7.31 | 8.81 | 6.14 | -17.0% | 19.1% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
ERIS Lifesciences Ltd is a pharmaceutical company based in India. The company primarily focuses on the manufacture and sale of pharmaceutical products and is known for its specialization in the chronic and lifestyle-related disorders segment, including cardiovascular, diabetes, gastroenterology, and dermatology. The company operates within the pharmaceutical industry, which is characterized by significant research and development activities to innovate and improve drug formulations. As of the available data, there are no specific recent major developments provided for ERIS Lifesciences Ltd.
Revenue
For the third quarter of fiscal year 2026 (Q3FY26), ERIS Lifesciences Ltd reported a total income of ₹807.47 crores, marking a 1.5% increase from the previous quarter (Q2FY26) which was ₹795.22 crores. In comparison to the same quarter in the prior year (Q3FY25), the total income reflected a 10.4% rise from ₹731.67 crores. These figures indicate the company's revenue growth on both a quarterly and annual basis. The increase in total income can be linked to the company’s ongoing operations and market demand for its products.
Profitability
ERIS Lifesciences Ltd's profitability metrics for Q3FY26 show a profit before tax (PBT) of ₹145.23 crores, which represents a decrease of 15.8% compared to the ₹172.39 crores recorded in Q2FY26. However, on a year-over-year basis, there was a 25.0% increase from the ₹116.16 crores in Q3FY25. The tax expense for Q3FY26 was ₹36.52 crores, slightly lower than the ₹38.20 crores in Q2FY26, but higher than the ₹29.23 crores in Q3FY25, indicating a year-over-year increase of 24.9%. The profit after tax (PAT) stood at ₹108.83 crores in Q3FY26, a decrease of 19.1% from the previous quarter's ₹134.47 crores, yet a 25.2% increase from ₹86.93 crores in the same quarter of the previous year. The earnings per share (EPS) for Q3FY26 was ₹7.31, down 17.0% from the ₹8.81 in Q2FY26, but 19.1% higher than the ₹6.14 in Q3FY25.
Operating Metrics
The total expenses for ERIS Lifesciences Ltd in Q3FY26 amounted to ₹645.00 crores, reflecting a 3.6% increase from Q2FY26, where expenses were ₹622.83 crores. There was also a year-over-year increase of 4.8% from the ₹615.51 crores recorded in Q3FY25. The data suggests an upward trend in operational spending, which may correlate with the company's expansion or increased production activities. These operating metrics provide insight into the cost structure and operational efficiency of ERIS Lifesciences Ltd, affecting overall profitability and financial health in the reported period.